文献速递神经肿瘤

应用统计决策树模型对新诊断胶质母细胞瘤进行个性化预后分层

Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model.
PubMed 文献 · J Neurooncol · 2024-04-19

该研究回顾性分析2010至2021年连续收治的462例胶质母细胞瘤患者,评估临床、影像和分子参数,以总生存为主要终点,识别最强预后因素并构建风险分层算法。结果显示查尔森合并症指数、肿瘤切除程度和辅助治疗是最强预后因素,基于这些因素的风险分层算法可实现诊断早期个性化预后估计。

要点

  • 查尔森合并症指数、肿瘤切除程度和辅助治疗是胶质母细胞瘤最强预后因素。
  • 查尔森合并症指数≤1且接受肿瘤切除者10个月生存几率最高为88%。
  • 查尔森合并症指数>3且未接受辅助治疗者10个月生存几率最低为0%。

核心结论

  • 基于显著预后因素的风险分层算法可在胶质母细胞瘤诊断时实现个性化早期预后估计,有助于更个性化的患者咨询。

研究设计与样本

  • 回顾性分析2010年至2021年间连续收治的经确认的胶质母细胞瘤患者队列,评估临床、影像和分子参数,以总生存为主要终点参数。

主要发现

  • 共分析462例胶质母细胞瘤患者,最强预后因素为查尔森合并症指数、肿瘤切除程度和辅助治疗。
  • 查尔森合并症指数≤1且接受肿瘤切除的患者10个月生存几率最高为88%。
  • 查尔森合并症指数>3且未接受辅助治疗的患者10个月生存几率最低为0%。
  • 查尔森合并症指数>3且接受辅助治疗的患者中,10个月生存率在70岁以下患者为56%,在70岁以上患者为22%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) is the most frequent glioma in adults with a high treatment resistance resulting into limited survival. The individual prognosis varies depending on individual prognostic factors, that must be considered while counseling patients with newly diagnosed GBM. The aim of this study was to elaborate a risk stratification algorithm based on reliable prognostic factors to facilitate a personalized prognosis estimation early on after diagnosis. METHODS: A consecutive patient cohort with confirmed GBM treated between 2010 and 2021 was retrospectively analyzed. Clinical, radiological, and molecular parameters were assessed and included in the analysis. Overall survival (OS) was the primary outcome parameter. After identifying the strongest prognostic factors, a risk stratification algorithm was elaborated with estimated odds of survival. RESULTS: A total of 462 GBM patients were analyzed. The strongest prognostic factors were Charlson Comorbidity Index (CCI), extent of tumor resection, and adjuvant treatment. Patients with CCI ≤ 1 receiving tumor resection had the highest survival odds (88% for 10 months). On the contrary, patients with CCI > 3 receiving no adjuvant treatment had the lowest survival odds (0% for 10 months). The 10-months survival rate in patients with CCI > 3 receiving adjuvant treatment was 56% for patients younger than 70 years and 22% for patients older than 70 years. CONCLUSION: A risk stratification algorithm based on significant prognostic factors allowed a personalized early prognosis estimation at the time of GBM diagnosis, that can contribute to a more personalized patient counseling.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Conrad K, Löber-Handwerker R, Hazaymeh M, et al. Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model. J Neurooncol. 2024. PMID: 38639854. doi:10.1007/s11060-024-04683-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。